Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma

Clemens Hinterleitner(University of Tübingen), K. Jaschonek(University of Tübingen), Klaus‐Peter Kreißelmeier(University of Tübingen), Ulrich Budde(Asklepios Klinik Altona), Lothar Kanz(University of Freiburg), Ann‐Christin Pecher(Center for Rheumatology), Hans‐Georg Kopp(Robert Bosch Hospital)

European Journal Of Haematology

September 21, 2019

10.1111/ejh.13331

Cited by 21

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

|The Lancet Oncology|2019|1.7k

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

|Current Drug Metabolism|2009|623

Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments]

|Blood|1994|431